NCT07446946Completed
Surgical Management of Pancreatic Cancer With Liver Metastasis (Oligometastasis)
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
Pancreatic cancer is one of the most serious forms of cancer. When it has already spread to the liver, treatment usually consists of chemotherapy rather than surgery. However, in recent years, some hospitals have begun removing both the pancreatic tumor and liver metastases during the same operation in carefully selected patients. This approach remains controversial, and it is unclear how often it is performed in everyday clinical practice and whether it is safe. The aim of this study was to better understand current practice patterns in Germany and to evaluate the short-term safety of simultaneous pancreatic and liver surgery. Using nationwide hospital data, we examined all adult patients who underwent pancreatic resection for a malignant pancreatic tumor over a 14-year period. The study was designed to test several key hypotheses. First, we hypothesized that simultaneous resection of pancreatic tumors and liver metastases is not an exceptional event but is already being performed in routine clinical care. Second, we examined whether adding liver surgery increases the risk of dying during the hospital stay compared to pancreatic surgery alone. Third, we investigated whether the extent of liver resection (minor versus major anatomical procedures) influences perioperative risk. Finally, we assessed whether hospital experience and surgical case volume affect patient safety in this complex setting. Because the data were derived from a nationwide administrative registry, the study focuses on short-term outcomes during hospitalization. It does not address long-term survival or the overall oncologic benefit of combined surgery. Instead, the purpose of this analysis is to provide objective real-world data on how frequently this surgical strategy is used and whether it appears to be feasible from a perioperative safety perspective.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 68303 (actual)
- First submitted
- 26 Feb 2026
- Start date
- 1 Jan 2010
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Richard Hunger
- Diseases
- Pancreatic cancer
- NCT number
- NCT07446946
What you commit to
- Study type: Observational
- Participants enrolled: 68303
- From 1 Jan 2010 to the primary completion date, 31 Dec 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- transplantation procedures
- Patients with a total pancreatectomy following a partial pancreatic resection during the same hospitalization
Age
- Missing data on age or sex
Who the study is looking for
- C25 as primary diagnosis
- pancreatic resection (OPS:5-524, 5-525)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.